Phase I/II Trial of Azacytidine + R-CHOP in Diffuse Large B-Cell Lymphoma
Update: this study is closed to enrollment.
Significant progress has been made in treatment of diffuse large B-cell lymphoma (DLBCL), but some patients are still not cured of their disease. Recently, researchers have begun to understand how reversible changes in expression of genes contribute to development of cancer and allow cancer cells to become resistant to the effects of chemotherapy. These reversible changes are termed “epigenetics” since they do not involve mutations in genes themselves.
We are working to take advantage of the reversible nature of these changes by pre-treating patients with azacitidine, a drug which reverses epigenetic changes, before starting standard chemotherapy treatment. In this way, we hope to improve the sensitivity of lymphoma cells to chemotherapy.
Key eligibility:
- Men and women age 18 and older
- Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL)
- Stage II, III or IV disease
- No previous treatment
- Detailed eligibility discussed when you contact the study team
For more information about this study, contact June Greenberg, RN at (212) 746-2651 or email June at jdg2002@med.cornell.edu.
Click here to view all our current trials for lymphoma and other cancers and blood disorders.
New Developments in Lymphoma 